Contact
searchSearch
HMP Global

Chronic Myeloid Leukemia Topic Center

Featured Article

News
Generic Imatinib Efficacy Comparable to Original for Chronic Myeloid Leukemia
12/28/2021
Jolynn Tumolo
Generic versions of imatinib were comparable in bioequivalence and bioavailability to the branded drug across studies, according to recent findings.
Generic versions of imatinib were comparable in bioequivalence and bioavailability to the branded drug across studies, according to recent findings.
Generic versions of imatinib...
12/28/2021
First Report Managed Care
News
Comparative Effectiveness of Asciminib vs Bosutinib for CML in Chronic Phase
12/07/2021
Jolynn Tumolo
Among patients with chronic myeloid leukemia who had already been treated with at least two tyrosine kinase inhibitors, asciminib resulted in greater major molecular response than bosutinib.
Among patients with chronic myeloid leukemia who had already been treated with at least two tyrosine kinase inhibitors, asciminib resulted in greater major molecular response than bosutinib.
Among patients with chronic...
12/07/2021
First Report Managed Care
News
In Real-World Setting, Treatment Efficacy for CML in Line With Promising Recent Data
12/01/2021
Jolynn Tumolo
Researchers concluded that asciminib was safe and effective in patients with chronic myeloid leukemia who did not benefit from alternative treatments in clinical practice.
Researchers concluded that asciminib was safe and effective in patients with chronic myeloid leukemia who did not benefit from alternative treatments in clinical practice.
Researchers concluded that...
12/01/2021
First Report Managed Care
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
From Oncology
News
Increasing TKI Utilization and Costs for CML Put Pressure on Medicare Part-D Insurers
09/20/2021
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for...
09/20/2021
Journal of Clinical Pathways
From Journal of Clinical Pathways
News
Treating CML: Combination Therapies, TKI Efficacy, Achieving Treatment-free Remission
03/12/2021
Maria Asimopoulos
“With the increasing discovery of the involvement of further molecules and pathways, we believe the scientific community will—at some point—be able to achieve TFR in our patient population and, finally, target and eradicate CML once and for...
“With the increasing discovery of the involvement of further molecules and pathways, we believe the scientific community will—at some point—be able to achieve TFR in our patient population and, finally, target and eradicate CML once and for...
“With the increasing discovery...
03/12/2021
First Report Managed Care
News
Comparative Effectiveness of Nilotinib and Imatinib for Long-term Outcomes in CML
03/09/2021
Maria Asimopoulos
“Overall efficacy and safety results support the use of nilotinib 300 mg [twice daily] as frontline therapy for optimal long-term outcomes, especially in patients aiming for [treatment-free remission],” researchers concluded.
“Overall efficacy and safety results support the use of nilotinib 300 mg [twice daily] as frontline therapy for optimal long-term outcomes, especially in patients aiming for [treatment-free remission],” researchers concluded.
“Overall efficacy and safety...
03/09/2021
First Report Managed Care
News
Tyrosine Kinase Inhibitor Discontinuation Safe in Patients With Chronic Myeloid Leukemia
02/18/2021
Maria Asimopoulos
“Our results provide important new information to inform the discussion between patients with CML and clinicians about the risks and benefits of TKI discontinuation and the potential to assess TKI cessation more accurately,” researchers...
“Our results provide important new information to inform the discussion between patients with CML and clinicians about the risks and benefits of TKI discontinuation and the potential to assess TKI cessation more accurately,” researchers...
“Our results provide important...
02/18/2021
First Report Managed Care
News
FDA Grants Full Approval to Synribo (Omacetaxine Mepesuccinate) for Chronic Myeloid Leukemia
02/14/2014
The FDA granted full approval on Thursday for Synribo (omacetaxine mepesuccinate), according to a news release from Teva Pharmaceuticals, the drug's manufacturer. The injectable drug was initially approved under the FDA's accelerated approval...
The FDA granted full approval on Thursday for Synribo (omacetaxine mepesuccinate), according to a news release from Teva Pharmaceuticals, the drug's manufacturer. The injectable drug was initially approved under the FDA's accelerated approval...
The FDA granted full approval on...
02/14/2014
First Report Managed Care

Newsfeed

News
Generic Imatinib Efficacy Comparable to Original for Chronic Myeloid Leukemia
12/28/2021
Jolynn Tumolo
Generic versions of imatinib were comparable in bioequivalence and bioavailability to the branded drug across studies, according to recent findings.
Generic versions of imatinib were comparable in bioequivalence and bioavailability to the branded drug across studies, according to recent findings.
Generic versions of imatinib...
12/28/2021
First Report Managed Care
News
Comparative Effectiveness of Asciminib vs Bosutinib for CML in Chronic Phase
12/07/2021
Jolynn Tumolo
Among patients with chronic myeloid leukemia who had already been treated with at least two tyrosine kinase inhibitors, asciminib resulted in greater major molecular response than bosutinib.
Among patients with chronic myeloid leukemia who had already been treated with at least two tyrosine kinase inhibitors, asciminib resulted in greater major molecular response than bosutinib.
Among patients with chronic...
12/07/2021
First Report Managed Care
News
In Real-World Setting, Treatment Efficacy for CML in Line With Promising Recent Data
12/01/2021
Jolynn Tumolo
Researchers concluded that asciminib was safe and effective in patients with chronic myeloid leukemia who did not benefit from alternative treatments in clinical practice.
Researchers concluded that asciminib was safe and effective in patients with chronic myeloid leukemia who did not benefit from alternative treatments in clinical practice.
Researchers concluded that...
12/01/2021
First Report Managed Care
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Increasing TKI Utilization and Costs for CML Put Pressure on Medicare Part-D Insurers
09/20/2021
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for patients with CML and the increase in TKI drug prices place considerable financial pressure on Medicare part-D insurers.
The increase in use of TKIs for...
09/20/2021
Journal of Clinical Pathways
News
Treating CML: Combination Therapies, TKI Efficacy, Achieving Treatment-free Remission
03/12/2021
Maria Asimopoulos
“With the increasing discovery of the involvement of further molecules and pathways, we believe the scientific community will—at some point—be able to achieve TFR in our patient population and, finally, target and eradicate CML once and for...
“With the increasing discovery of the involvement of further molecules and pathways, we believe the scientific community will—at some point—be able to achieve TFR in our patient population and, finally, target and eradicate CML once and for...
“With the increasing discovery...
03/12/2021
First Report Managed Care
News
Comparative Effectiveness of Nilotinib and Imatinib for Long-term Outcomes in CML
03/09/2021
Maria Asimopoulos
“Overall efficacy and safety results support the use of nilotinib 300 mg [twice daily] as frontline therapy for optimal long-term outcomes, especially in patients aiming for [treatment-free remission],” researchers concluded.
“Overall efficacy and safety results support the use of nilotinib 300 mg [twice daily] as frontline therapy for optimal long-term outcomes, especially in patients aiming for [treatment-free remission],” researchers concluded.
“Overall efficacy and safety...
03/09/2021
First Report Managed Care
News
Tyrosine Kinase Inhibitor Discontinuation Safe in Patients With Chronic Myeloid Leukemia
02/18/2021
Maria Asimopoulos
“Our results provide important new information to inform the discussion between patients with CML and clinicians about the risks and benefits of TKI discontinuation and the potential to assess TKI cessation more accurately,” researchers...
“Our results provide important new information to inform the discussion between patients with CML and clinicians about the risks and benefits of TKI discontinuation and the potential to assess TKI cessation more accurately,” researchers...
“Our results provide important...
02/18/2021
First Report Managed Care
News
FDA Grants Full Approval to Synribo (Omacetaxine Mepesuccinate) for Chronic Myeloid Leukemia
02/14/2014
The FDA granted full approval on Thursday for Synribo (omacetaxine mepesuccinate), according to a news release from Teva Pharmaceuticals, the drug's manufacturer. The injectable drug was initially approved under the FDA's accelerated approval...
The FDA granted full approval on Thursday for Synribo (omacetaxine mepesuccinate), according to a news release from Teva Pharmaceuticals, the drug's manufacturer. The injectable drug was initially approved under the FDA's accelerated approval...
The FDA granted full approval on...
02/14/2014
First Report Managed Care
News
Linvoseltamab Demonstrates Improved Efficacy for Patients With TCE RRMM
05/14/2026
Rebecca Amrick
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed real-world treatment regimens for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM), with higher response rates and more durable outcomes in the LINKER-MM1 trial.
Linvoseltamab outperformed...
05/14/2026
First Report Managed Care
News
IMC Care Matches ICU Outcomes for Hypertensive Emergencies, Study Finds
05/04/2026
Rebecca Amrick
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with...
05/04/2026
First Report Managed Care
News
Adjuvant Immunotherapy Costs Challenge Lung Cancer Affordability
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
Hemodialysis Triggers Wide Epigenetic Changes in Patients With Chronic Kidney Disease
04/27/2026
Rebecca Amrick
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study...
04/27/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Semaglutide Shows Health Benefits for CVD but Falls Short on Cost-Effectiveness at Current Drug Prices
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use